liraglutide · Novo · NDA 206321
Saxenda
Earliest generic entry, as listed
9 Jul 2037
Blocked by patent: US 9968659 (pediatric extension).
Listed patents · 1 unexpired
2 Orange Book listing rows for 1 patent, including 1 pediatric extension. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.
| Patent | Claims | Expires |
|---|---|---|
| US 9968659 | use U-2438 | 9 Jul 2037 |
| US 9968659 listing row | use U-2438 | 9 Jan 2037 |
| US 9968659 listing row | pediatric extension · sets the listed date | 9 Jul 2037 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 206321 · 001 · RLD | solution, subcutaneous | 18MG/3ML (6MG/ML) | 9 Jul 2037 |
Expired or delisted (2)
- US 8114833 · — · 13 Feb 2026
- US 8114833 · product · 13 Aug 2025